Brainstorm Cell Therapeutics Inc.
BCLI· OTC
BCLIBrainstorm Cell Therapeutics Inc.
Filed Nov 14, 2025 · 10-Q · 45 days after period end · 0001104659-25-112701
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Net Income | -$2.11M | -$2.71M | -$1.23M | -$6.86M |
| EPS Diluted | -$0.19 | -$0.51 | -$0.45 | -$0.19 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Brainstorm Cell Therapeutics Inc. · CIK 1137883 · Engraved from SEC EDGAR
ended Sep 30, 2025 · filed Nov 14, 2025 · 45 d after period end
